AM-Pharma B.V., a Bunnik, The Netherlands-based biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) for treatment of severe inflammatory diseases, has raised €29.2m in Series D financing.
The round was led by Ysios Capital Partners, co-led by Kurma Life Science Partners and supported by Abbott, Shire, BB Biotech Ventures, Idinvest Partners, Forbion Capital Partners and Inventages Venture Capital.
The company intends to use the funds to advance its human recombinant form of human AP from preclinical stages through to the end of phase II as a treatment for Acute Kidney Injury (AKI).
AKI is a serious condition in which the kidney function is damaged by severe inflammation (sepsis), surgery or contrast fluids.
In conjunction with the financing, Joël Jean-Mairet of Ysios, Remi Droller of Kurma Life Sciences Partners and Klaus Breiner of BB Biotech Ventures will join the company’s Supervisory Board comprising of Ashok Dhanrajgir, Bart Bergstein, David Brister and Eric Claassen.
AM-Pharma is led by CEO Erik van der Berg.